Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

1.19
+0.03002.59%
Post-market: 1.200.0100+0.84%17:49 EST
Volume:4.11M
Turnover:4.70M
Market Cap:8.86M
PE:-0.37
High:1.31
Open:1.15
Low:1.03
Close:1.16
52wk High:3.85
52wk Low:0.2810
Shares:7.44M
Float Shares:7.33M
Volume Ratio:0.05
T/O Rate:56.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2501
EPS(LYR):-12.6857
ROE:-89.90%
ROA:-53.70%
PB:0.73
PE(LYR):-0.09

Loading ...

Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Dow Jones
·
Yesterday

Form 4 | Pasithea Therapeutics Corp. Director Lawrence Steinman purchased 133,333 Shares.

Filings Track
·
Dec 01

Pasithea Therapeutics Director Lawrence Steinman Reports Acquisition of Common Shares

Reuters
·
Dec 01

Pasithea Therapeutics Director Simon Dumesnil Acquires Common Shares

Reuters
·
Dec 01

US Equity Markets Close Higher During Thanksgiving Week as Interest Rate Cut Expectations Remain Strong

MT Newswires Live
·
Nov 29

Top Midday Gainers

MT Newswires Live
·
Nov 29

Crude Oil Gains 1%; Tilray Brands Shares Plunge

Benzinga
·
Nov 29

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM

Reuters
·
Nov 28

Pasithea Therapeutics prices 80M shares at 75c in public offering

TIPRANKS
·
Nov 28

Pasithea Therapeutics Corp - Cash Position to Extend Runway Through First Half of 2028

THOMSON REUTERS
·
Nov 28

Pasithea Therapeutics Corp - Prices Public Offering of 80 Mln Shares at $0.75 Each

THOMSON REUTERS
·
Nov 28

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

GlobeNewswire
·
Nov 28

3 Penny Stocks to Watch Now, 11/27/25

TIPRANKS
·
Nov 27

Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today

Benzinga_recent_news
·
Nov 26

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:44 AM

Reuters
·
Nov 26

Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004

TIPRANKS
·
Nov 26

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

GlobeNewswire
·
Nov 25

Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1

Reuters
·
Nov 25

BRIEF-Pasithea Therapeutics Announces Completion Of Cohort 7 In Ongoing Phase 1 Trial Of Pas-004

Reuters
·
Nov 24

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

TIPRANKS
·
Nov 24